The impact of current investigational drugs for acne on future treatment strategies.
Expert Opin Investig Drugs
; 33(2): 127-132, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38369920
ABSTRACT
INTRODUCTION:
Acne vulgaris is one of the most prevalent diseases worldwide with a considerably high cost and a burden on quality of life. There are currently many topical and systemic therapies for acne; however, many are limited by their local adverse event profile. This review provides an update on current, novel Phase I and II trials for acne vulgaris. AREAS COVERED This review searched the National Institutes of Health US National Library of Medicine online database of clinical trials (ClinicalTrials.gov) for ongoing Phase I and II trials. Only papers discussing novel therapies were discussed, and combinations of previously FDA-approved drugs were excluded. EXPERT OPINION The current investigational approaches to acne treatment reflect an attempt to mitigate the underlying cause of acne pathogenesis. By targeting key mechanisms involved, studies aim to show long-term improvement with less frequent treatment use. This provides potential for more tolerable treatments with better patient adherence, in turn leading to increased efficacy.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Drogas en Investigación
/
Acné Vulgar
Límite:
Humans
Idioma:
En
Revista:
Expert Opin Investig Drugs
/
Expert opin. investig. drugs
/
Expert opinion on investigational drugs
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos